- Title: Subtitle
- Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (coBRIM-B)
- Creators
- Melissa K. Yee - UPMC Hillman Cancer CenterYan Lin - UPMC Hillman Cancer CenterVikram C. Gorantla - University of PittsburghLisa H. Butterfield - UPMC Hillman Cancer CenterHarriet M. Kluger - Yale UniversityPaul B. Chapman - Memorial Sloan Kettering Cancer CenterTara C. Gangadhar - University of PennsylvaniaMohammed M. Milhem - University of IowaAnna C. Pavlick - New York UniversityRavi K. Amaravadi - University of PennsylvaniaLynn Mara Schuchter - University of PennsylvaniaAhmad A. Tarhini - UPMC Hillman Cancer CenterJohn M. Kirkwood - University of PittsburghHussein Abdul-Hassan Tawbi - UPMC Hillman Cancer Center
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.33(15_suppl), pp.TPS9088-TPS9088
- DOI
- 10.1200/jco.2015.33.15_suppl.tps9088
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2015
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984363313102771
Abstract
Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (coBRIM-B)
Journal of clinical oncology, Vol.33(15_suppl), pp.TPS9088-TPS9088
05/20/2015
DOI: 10.1200/jco.2015.33.15_suppl.tps9088
Details
Metrics
8 Record Views